reported a case of grade IV therapy-resistant acute GVHD of the gut and liver that showed rapid improvement after infusion of mesenchymal stem cells (MSCs). We here report a pilot study using human adipose tissuederived MSC (AMSC) to treat severe acute GVHD after ASCT.
A 38-year-old female with acute lymphocytic leukemia in second remission received a transplant of hematopoietic stem cells (HSCs) from a human lymphocyte antigen (HLA)-identical unrelated female donor after conditioning with Ara-C (4 g/m 2 /day) intravenously (i.v.) on days À10 to À9; busulfan (4 mg/kg/day) orally on days À8 to À6; cyclophosphamide (1.8 g/m 2 /day) i.v. on days À5 to À4; Me-CCNU (250 mg/m 2 ) orally once on day À3. Immunosuppression included ATG (thymoglobulin, 2.5 mg/kg/day; Sang Stat, Lyon, France) i.v. for 4 consecutive days, on days À5 to À2 during the conditioning, followed by a combination of cyclosporine A (CsA), a short course of mycophenolate mofetil (MMF) and four doses of methotrexate (MTX). On day þ 21, the patient developed a maculopapular rash of the thorax and back that progressed despite treatment with prednisolone (2 mg/kg/day). On day þ 38, the patient developed severe diarrhea (41200 ml/ day) and abdominal pain requiring morphine, and then she stopped eating and was treated with total parenteral nutrition (TPN). Colonoscopy showed moderate-to-severe acute GVHD. The serum total bilirubin level exceeded 230 mmol/l, and serum alanine aminotransferase (ALT) concentration was higher than 400 U/l. Extracorporeal psoralen-enhanced UVA light treatment (three times per week) was tried for 6 weeks. Methylprednisolone (500 mg/ day), infliximab (10 mg/kg) and daclizumab (1 mg/kg) were ineffective. MMF, tacrolimus and MTX were also tried. Colonoscopy on day þ 62 showed grade IV GVHD. In conclusion, this patient seemed to be unresponsive to all types of immunosuppression. At the same time, she was treated for repeated bacterial, viral and invasive fungal infections.
We chose an unrelated mismatched male donor because there were no readily available HLA-identical donors or haplo-identical family donors and because major histocompatibility complex (MHC)-compatibility is not necessary for mesenchymal stem cell immunosuppression. 7, 8 After the ethics committee at Henan Tumor Hospital approved the study and the donor gave written informed consent, AMSCs were isolated as described previously. 9 Briefly, subcutaneous abdominal adipose tissue obtained from the donor undergoing plastic surgery (lipectomy) was digested by use of collagenase (300 U/ml in phosphatebuffered saline (PBS), 2% bovine serum albumin) for 45 min under constant shaking. After removal of the floating mature adipocytes and erythrocytes, the lower layer was centrifuged (200 g, 10 min). After successive filtrations through 100-, 70-and 40-mm sieves, the cells were washed with PBS/2% fetal calf serum (FCS) (Gibco Life Technologies, Paisley, UK) for two times and then plated in polystyrene flasks at a density of 2 Â 10 6 /ml. Selective expansion medium contained 57% Dulbecco's modified Eagle's medium/F-12 (Gibco), 40% MCDB-201 (Sigma, St Louis, MO, USA), 2% FCS, 1 Â insulin transferrin selenium (Gibco), 1 Â insulin transferrin selenium (Gibco), 10 À9 M dexamethasone (Sigma), and 10 À4 M ascorbic acid 2-phosphate (Sigma), 10 ng/ml epidermal growth factor (Sigma), 10 ng/ml PDGF-BB (Sigma), 100 U/ml penicillin and 1000 U/ml streptomycin (Gibco). Once adherent cells were more than 70% confluent, they were detached with 0.125% trypsin and 0.01% ethylenediaminetetraacetic acid and replated under the same culture conditions. After 3 weeks cell culture, 1.0 Â 10 8 AMSC were harvested. As we described previously, 9 these cells expressed fetal liver kinase, CD105, CD44, and CD29, but not CD34, CD45 or CD14. A dose of 2 Â 10 6 AMSC per kg of the patient's weight was given i.v. on day þ 69.
There were no incidences of AMSC infusion-related toxicity. A complete resolution of diarrhea and significant improvement of skin and liver disease were observed. Briefly, diarrhea decreased from 9-15 times daily (41500 ml/day) to 2-5 times daily (o500 ml/day). A decline in total bilirubin and ALT was noted 6 days after the AMSC transplantation, and skin rash disappeared. Two weeks later, stools normalized and TPN was discontinued. On day þ 100, minimal residual disease (MRD) was analyzed as Pongers-Willemse et al. 10 described, and the result was positive. So CsA treatment was discontinued to allow maximum graft-versusleukemia (GVL) effect. On þ day 116, the patient again had diarrhea and mild abdominal pain. Colonoscopy showed mild-to-moderate acute GVHD and 8% male epithelium by fluorescence in situ hybridization (FISH; Figure 1a and b). In addition, PCR analysis of the male-specific Sry gene confirmed the presence of AMSC donor-derived cells in the colon (Figure 1c ). She received a transplant of the same batch of AMSC from the donor (1 Â 10 6 /kg) on day þ 127. After 1 week, stools were normal and she started to eat again. Bilirubin and ALT also returned to normal 2 weeks later. She was discharged from the hospital on day þ 151 and is now well 397 days after ASCT with no MRD in blood and bone marrow.
Several effects have been noted in this pilot study. First, no side effects were noted after the infusion of HLA-mismatched AMSC; secondly, AMSC dramatically affected tissue repair of severe acute GVHD of the gut and the liver, and it could be proven that the male epithelial cells in the colon detected by FISH were from the AMSC donor, because the HSC donor was female; thirdly, skin rash disappeared soon after AMSC infusion. In view of the dismal outcome in patients with grades III-IV acute GVHD, AMSC seems promising. However, there was just one patient in this pilot, so it is not completely confirmed that the positive effect seen is due to immunomodulation of GVHD in vivo, although there is no other explanation. We wanted to report the positive effects using AMSC for treatment of life-threatening acute GVHD at an early stage, because of the very poor outcome in such patients. We felt it was urgent to alert physicians treating such patients of this possibility. For ethical reasons, the primary evaluation point will be responsive within 2 weeks. Thereafter, the non-responders can be treated with any therapy, including AMSC. 
